Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Even if the plants are earthquake proof the disruption of a major earthquake would cause a lot of problems. Will the employees be able to go to work as usual? Not likely. Will deliveries and shipments proceed as usual? Not likely. Would the clients be happy without getting their products on time? Not likely.
For the "had it coming to them" crowd...LA Times piece mentions Irvine and Orange county...However the article's author is Rong-Gong (not making it up)... https://www.msn.com/en-us/news/us/this-little-known-earthquake-fault-has-been-quiet-but-it-can-unleash-devastation-across-socal/ar-AA1CZCYE ....r
Just here to say to all I was in until the end as I promised. Someone just found out my 15k shares sold off in cash sale.
Feels like what has always happened and no recourse again. Good Luck to all PGG
Fond memories of Frootie and his "blastysplat." Frootie, as I was told long ago, is actually a very successful money professional and investor. Remember Webby from Techniclone days? He built a website for investors in that entity, and was around when we ran from sub-$1 to $16. We all did very well. Terry Dye, Col. Gaddy, KAtie Scarlet O'Hara, along with many of the recent names now posting on this board...what a long, strange trip it's been. Thanks for NMRA, investorcg - looks interesting, Nice cash runway, too! Before this board disappears, may I suggest you check out 'Rani Therapeutics" (RANI). The founder has developed a pill that could revolutionize drug delivery, without shots or IV's. There's also a weight loss component to the potential broad use of the pill. The company founder is a very successful player in bio, who has had over half of his 20 start-ups bought out. High insider ownership, Lots to like here, for "a dollar and a dream." Best of luck to all of you, and thanks again for all of your great insights over the years.
Now that we are officially cooked, will the real FROOTIE please stand up and identify yourself!!!!
I'm moving my focus to $NMRA now for a dollar and a dream. Trading at less than cash value, and just named new CEO, who is a venture capital guy over at ARCH Venture. 7-8 drugs in pipeline. Just had poor data from 1 of 3 concurrent trial for depression, and stock went down 85%, a total overblown reaction.
RIP to TCLN, PPHM and CDMO. Screwed to investors.
Avid was bought out and we all became millionaires lol
I’m sun tanning on my new yacht right now.
We dumped our share count awhile ago, what exactly happened that it is no longer listed?? Pour souls holding this thing got the dagger???
Pretty good deal. Destroy the company financially and pick up $12 million
All the RSU's PSU's and remaining ESOP shrs were disposed of on friday...here's Greens' haul... https://www.sec.gov/Archives/edgar/data/704562/000168316825000856/xslF345X05/ownership.xml ...r
Avid stepping up their game now that they are in private hands.
TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid’s elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers.
The reimagined Avid website captures the company’s elevated brand through the tagline, “Discover the Avid effect.™”, helping educate visitors on the differentiation that positions the company as one of the industry’s leading, most trusted biologics CDMOs. It offers a completely revamped customer experience highlighted by user-friendly navigation, improved accessibility, video interaction, and educational resources.
“As a company that places the highest priority on delivering exceptional quality service and exceeding the expectations of our customers, we felt compelled to bring that same ethos to our online presence,” said Nick Green, president and chief executive officer of Avid. “We take great pride in unveiling our new company website as a showcase to the Avid brand, capturing the spirit of our team, our unrivaled expertise, world-class facilities, and personalized process. For those that already have a relationship with Avid, we expect the new site will align with their experience. For those just getting to know us, we hope it will serve as a trusted and valuable resource for exploration, education, and engagement.”
It was strange that OncXerna closed the doors when I was questioning with the SEC why Oncxerna seemed to be slow walking Bavi with exclusively never ending phase 2 trials. Rolf indicated he was out of the loop but also found it strange that Bavi was still in phase 2 trials. And yes it was phase 3 trials that revenues would begin to be paid out to Avid. In my opinion this was all very strange.
Now it could be OncXerna just couldn't finance a phase 3 trial with royalties being paid out. But with the low ball buyout I just have to wonder.
Any $$$s actually change hands under that licensing agreement? Has Bavituximab ever been marketed? Or FDA-approved for marketing?
Oncologie is defunct or bankrupt.
It was all about Bavi, nothing more nothing less..
This was all planned out years ago, I'm pretty sure I mentioned this when I heard of the buyout.
Not a damn thing we can do about it either.
Just disgusting what happened.
THANX!!! THIS IS CRIMINAL ACTIVITY & SHOULD INVESTIGATED!!! SHAREHOLDERS ARE THE VICTIMS OF DRUG TRIAL FRAUD; OF MANAGEMENT & ACCOUNTING SUBVERSIVE FRAUD; OF PPS SUPPRESSION FOR EVENTUAL THIEVING TAKEOVER!!!! SEC SHOULD BE NOTIFIED FOR ACTION FOR US SHAREHOLDERS!!! SHAME THAT THEY ALL SPIT UPON DR THORPE"S WORK AND DISCOVERIES!!!! _____ F R A U D!!!!!!!!!!! _____
Bavi being revived -- Very Predictable. Yes this was all planned. Just as a reminder.
Royalty rate:
9,00 %; 11,00 %; 13,00 %; 14,00 %; 16,00 %
Base:
Net sale
Other payments:
Licensee shall pay to licensor the following payments: $3,000,000; $3,000,000; $2,000,000; Licensee shall pay to licensor the following milestone payments: $1,000,000; $2,000,000; $8,000,000; $5,000,000; $4,000,000; $30,000,000; $25,000,000;no $15,000,000; $5,000,000; In the event of licensee's sublicensing, licensee shall pay to licensor the following sublicensing revenue share percentage payments as follows: an amount equal to 0,30 multiplied by aggregate Phase II sublicensing revenue received by licensee and its affiliates (from or in all countries and territories) during the applicable quarter, or an amount equal to 0,15 multiplied by aggregate Phase III sublicensing revenue received by licensee and its affiliates (from or in all countries and territories) during the applicable quarter.
Compensation details:
Licensee shall pay to licensor royalty fees as follows: an amount equal to 9% of aggregate net sales (in all countries and territories) of up to $100,000,000 of each product; An amount equal to 11% of aggregate net sales (in all countries and territories) from $100,000,001 to $200,000,000 of each product; An amount equal to 13% of aggregate net sales (in all countries and territories) from $200,000,001 to $500,000,000 of each product; An amount equal to 14% of aggregate net sales (in all countries and territories) from $500,000,001 to $1,000,000,000 for each product; An amount equal to 16% of aggregate net sales (in all countries and territories) equal to or greater than $1,000,000,001 for each product.
Also the manufacturing rights were Avid's!
Per Google, The Bavituximab Patent Has Been Revised...
Google link:
https://patents.google.com/patent/US20180289771A1/en
Imho, Someone Manipulated Sale Of $CDMO
And Stole It And This Patent From StockHOLDers!
Patent Expiration Now Revised To:
"Status-Active, 2038-05-30 Adjusted expiration"
Per Google, The Current Assignees:
"Oncxerna Therapeutics Inc Avid Bioservices Inc"
And We Know Oncxerna Became Oncologie
And Is Now Defunct, Which Means
Avid's New Owners Retain 100% Of Patent.
Also, USPTO.gov Shows NO RESULTS FOUND
When Searching For Patent US20180289771A1,
Avid Bioservices, OR Bavituximab.
So, The Apparent Theft Seems Complete...
(All in my humble opinion).
Glta Retail Stock Investors In Future Investments!
Me too. Guess that wraps this up. GLTA, thus ends many years of hope, excited anticipation, catastrophic disappointment and more recently sadness.
FYI, Schwab Issued My CDMO Cash. Glt AllOfYou,eom.
Schwab posted a comment in "Schwabese" on my CDMO shares that seems to indicate that today is the day of a "forced sale". I expect my $ in the morning. We'll see.
Today's WSJ repeats the news from CNBC-TV, reporting that NVO "has committed billions of dollars to new manufacturing capacity on top of an $11 billion deal to buy three manufacturing sites previously owned" by Catalent. Capital expenditure plans have been increased by~ 18 billion kroner to a total of 65 billion kroner in 2025, mainly due to capacity investments. WSJ, pages B1-B2. 10,000 DKK= about $1,386.
More and more uses for the compound which means a lot more demand.
What an absolute steal.
And Avid sits with idle capacity.
Quite the Sales and Finance team Nick put together!
Despite all the disasters (including the sale) most of the folks on this board made some money.
But that was to the genius of building out a CDMO with the potential of Bavi.
Incredibly, Nick and management team somehow destroyed shareholder value by expanding capacity.
A fitting ending would be if Jeanette was running the Hedge Fund that did the buyout
God's speed everyone for enduring.
PFE's acquisition of Hospice in 2015 gave it that capacity. Now I just saw NBC-TV report that weight-loss drugs might cure an addiction to alcohol, per a study in Tulsa, Oklahoma.
Now I wonder whether we Avid shareholders might see a few more $$$/share in any takeover to avoid a shareholder class action suit led by other institutional investors. That would be a deserved, pleasant surprise.
NVO CEO interview today on CNBC today. Wegovy sales up, demand exceeding expectations, looking for more supply. I will be surprised if negotiations for sale of CDMO to NVO are not near completion, maybe tonight. NVO was reported to be the most valuable pharm company in Europe weeks ago. Has a solution to HALO's problem been solved by having 2 locations with trade secrets somehow preserved?
Ya think. Should be useful fodder for lawyers.
YES, GREAT GROWTH POTENTIAL GOING FORWARD, ""BUT; WITHOUT ITS LONGSTANDING, LOYAL SHAREHOLDERS WHOM HAVE PERSEVERED THROUGH YEARS OF DROUGHT, THROUGH PPS RISES, AND PRECIPITOUS DROPS!!!!"" ______ IMMORAL MANAGEMENT OF BOTH ACQUIRERS AND THE ACQUIRED!!!!!
Hmmm...Sounds a little contradictory to what they've been telling us.....
https://finance.yahoo.com/news/avid-bioservices-poised-significant-growth-145500934.html
">Sargent Investment Group LLC cut its stake in Avid Bioservices, Inc. by 32.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 377,694 shares of the biopharmaceutical company's stock after selling 180,936 shares during the period. Sargent Investment Group LLC owned 0.59% of Avid Bioservices worth $4,695,000 as of its most recent filing with the Securities & Exchange Commission
"https://www.marketbeat.com/instant-alerts/avid-bioservices-inc-nasdaqcdmo-shares-sold-by-sargent-investment-group-llc-2025-02-05/">https://www.marketbeat.com/instant-alerts/avid-bioservices-inc-nasdaqcdmo-shares-sold-by-sargent-investment-group-llc-2025-02-05/</a><br>
Shares are halted today.
But feel free to contact Stephanie.
She has always been a wealth of information 🤣
SADLY OR VERY SADLY I'M OUT
AT $12.50 YESTERDAY WAITED MOSTLY FOR MAX RIPPOFF PRICE?? It's been real, and an honor pleasure to moderate his board for several years, and being in contact with so many other long-standing shareholders since 1997 here!! Sadly, many passed away before this ever got to fruition of Bavutuxiimab and PPHM Having and showing great success!
Now, on hindsight, the build outs were a joke, Management and the accountants were and are just Disreputable, immoral, untruthful and bothering on criminal!
The only time I sold in the last 28 years, was when The share price was over $34 a share praise God!
Now settling for 1250 a share is not the end of the world, but it is a slap in the face and I hit to the pocket!
Current management has dishonored and be Smurfs the name of Dr. Philip Thorpe imho!!
This little company was destined to become a gem in the biotech world; Until she or evil and underhanded entities and people sabotage this company and the trials, forcing the sale of Bavi and making the sub secretary of AVID THE FACE AND EQUITY OF THE COMPANY KNOWN AS CDMO!
I'm sure this board will go away shortly so I won't even bother resigning as moderator and I will still check in because I have many friends here! Blessings to all, and I hope you red deploy the assets for good use and good profits in the future to help circumvent the Al Capone and Bonnie and Clyde Management of CDMO!
I Believe They Stated In The Sale Propaganda...
That they intended to finalize the sale within 3 days after the vote to confirm sale,
But I could be wrong.
Can someone else check/confirm?
There has been no communication that I have seen since the vote happened.
Personally, I was planning on getting it tomorrow, lol...
Hello,
I assume CDMO is close to going private with the stock trading at $12.50.
Has there been a firm date yet when the stock is turned to cash?
What Happens IF Shorts Cover Before EndOfDay? Will...
The PPS Go up, Up, UP,...?
Or Have The Shorters Already Arranged To Cover "Off Market",
Behind Closed Doors?
Fintel Still Shows 124% Owned By Institutional Investors!?!?
https://fintel.io/so/us/cdmo
Glta $CDMO StockHOLDers!
Couldn't determine North. Only thing I saw was that Pfizer has done their manufacturing for other licensed products.
I sold half my CDMO prior to the vote in case and didn't reinvest in stocks rather left it all in cash. If this dropped I was ready and I think your move echo's my sentiment. So I'll keep my powder dry, do the same when we get our $12.50
Agree. But if their actions weren't negligent and they pin it on someone else it is part of the reason why we don't have a case now.
Do we know what entity makes/manufactures AXSM's newly FDA-approved migraine drug Symbravo, expected to be introduced in next 4 months? It was approved by FDA last Friday, AH. CDMO might be an ideal candidate.
I sold all my stocks this morning. Trump has the record for 8 of 10 biggest drops in stock market history. I have no doubt he will improve on that performance. His biggest was -2997 points.
Dr. Rocker,- I think you are absolutely correct on what transpired and the collusion between the current and former board members.
Here is some additional food for thought. Now with the implementation of tariffs on imported goods and those manufactured outside of the US, can you imagine how the value of a US based CDMO (with excess capacity) just increased in value? I would suggest at least 50%.
This has to be one of the worst buyouts ever transacted (for shareholders).
I think we understand the impact of the last ill-advised financing and the almost insurmountable hurdle that caused but I still don't understand why operationally the new facility was not able to generate revenue? Their explanation of higher interest rates and less biotech research never made sense. Was it the wrong market and just a strategic blunder?
I think we understand the impact of the last ill-advised financing and the almost insurmountable hurdle that caused but I still don't understand why operationally the new facility was not able to generate revenue? Their explanation of higher interest rates and less biotech research never made sense. Was it the wrong market and just a strategic blunder? Also, whatever happened to that Belgium guy?
Avid Bioservices was incorporated in Delaware in 1996 via Techniclone and Peregrine. Avid conducts its business activities in California. A suit to recover our lost use of Capital due to managements' and auditor's gross (may be deliberate)negligence in 1) failure to timely check boxes on forms and 2) managing corporate finances in a fiduciary manner may be brought in Wilmington, Delaware or San Jose/San Diego, California, IMO. A graph of Avid share price illustrates the facts relating to our lost use of capital date wise, before and after expansion was started/completed. We know the financing facts--originally at low interest rates and subsequently at high interest rates. The party(John Doe) that caused any management "mistake" in 1) and 2) above would be included as a defendant in the complaint, as would the 2 funds that have negotiated/completed the buyout/merger transaction. See California v. Texas, 141 S.Ct. 2104, 2113(2021) and TransUnion, LLC v. Ramirez, 141 S.Ct. 2190, 2203-2204(2021). See also FRCP 23.1 and 18f-4 regarding 4 year timeliness, bond requirements, and shareholders who have rights to bring shareholder derivative suits. A demand letter to Avid management and BOD looks futile, hence unnecessary.
Spouse and I are contemplating a shareholder derivative suit as outlined above. Is anyone here interested? A $50k bond in California(?) is a substantial cost that could be split. I have contacted no institutional shareholders to determine their interest, nor have I been able to talk with attorneys I know to ascertain their interest.
But that won’t do us any good as the sale will have closed.
It seems they feel they were given bad legal guidance and might be pursuing an outside firm over this.
Wish I had FU money as I would sue just to depose them all. No one is going to convince me the financial screwup was not intentional. If not, why was no one held accountable.
We all thought Nick and gang were going to grow the pie and everyone would benefit but in reality Nick and gang only grew the portion of the pie the gang controlled thus squeezing shareholders out of a fair return.
I call them the gang because they are gangsters! Taking from people playing fairly.
Again this experience has opened my eyes the utter sleaze exists in this world and the things they get away with. I hope they can live happily with the money they have taken from good people thinking their wit makes them in titled to unearned fortunes
I hope the best to everyone who went through this little adventure!
Good luck!
I Suppose Anything's Possible, But Not Likely(shrug)...
Getting only $12.50/share is retail already getting taken advantage of, so,
I don't think there's any point to attract attention by not paying the $12.50/share.
But, I will also believe it when I see my cash...
Glta!
Followers
|
826
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
347006
|
Created
|
11/07/03
|
Type
|
Free
|
Moderators |
Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com
President/CEO: Nicholas Green (eff. 7-30-20 https://tinyurl.com/yczapcc7 )
Four Avid Fact Sheets a/o 2-2020: https://avidbio.com/resources/fact-sheets/
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.
12-2019/Video: Tour of Myford Facility (2mins.): https://vimeo.com/380135562
7-2020: AVID’s Push Towards cv19 (I don’t capitalize things I hate) contracts: https://tinyurl.com/y8wzgneh
UPCOMING EVENTS: https://avidbio.com/events/
Sep1(Tue): Q1/FY21 (qe 7-31-20) Financials & Conf. Call - Transcript: https://tinyurl.com/y329llow
Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.: https://tinyurl.com/y4cbjjrc
Sep21-24/Virtual: Biotech Week Conf., Boston
Sep21-24/Virtual: BioProcess Intl. US Wes Conf., Santa Clara CA
...Time TBD: Presentation by Haiou Yang, PhD "Facility-Fit Driven Dev. for a mAb Production Process"
Oct20 10amPT/VIRTUAL: Annual Shareholders Mtg. https://tinyurl.com/y28blkjn 14A Proxy: https://tinyurl.com/y46ga9el
...ASM Replay (9:45): https://www.virtualshareholdermeeting.com/CDMO2020 (Control# not needed)
Apr20-22 2021/Booth#1159: INTERPHEX, NYC
Dec2(Wed) after mkt: Q2/FY21 (qe 10-31-20) Financials & Conf. Call - Transcript: https://tinyurl.com/y66xk888
Dec14-17: Antibody Engineering & Therapeutics Conf., San Diego
Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
• IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com
SEC:
Latest 10Q 10-31-20 iss. 12-2-20 https://tinyurl.com/y3ournzr (Cash 10-31-20=$35.7mm)
Latest 10K 4-30-20 iss. 6-30-20 https://tinyurl.com/yak25nco (Cash 4-30-20=$36.3mm)
Latest DEF14A/Proxy iss. 8-27-20 (re: 10-20-20 ASM): https://tinyurl.com/y46ga9el
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea
Poison Pill adopted 3-16-06 for 10yrs: http://tinyurl.com/yvypvh 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6
...3-17-16 Poison Pill extended until 3-16-2021 https://tinyurl.com/y74glo2n (Form8A Amendment #1)
...Poison Pill TERMINATED eff. 9-23-2019 https://tinyurl.com/y2mzx3xo
SHARES:
Shares O/S as of 11-23-20=56,726,334 - history since 4-2006: https://tinyurl.com/y66xk888 (at bottom)
...A/O 10-31-20: 3,451,000 stock options outstanding at a wgt.avg. exercise price of $6.41 (pg.16 10Q).
...MarketWatch.com for CDMO (shows Float): https://www.marketwatch.com/investing/stock/cdmo
1-12-18: S-3 Shelf Registration filed for up to $125mm https://tinyurl.com/y9qtewpw
...12-14-20: Avid raises ~$34M gross, selling 3,833,335@9.00/sh. (underwriter: RBC Capital) https://tinyurl.com/y92yr9g4
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: https://tinyurl.com/ya3nenth 424B5: https://tinyurl.com/ycpshgxl
Total INST.+LARGE Holdings now 41,617,965 73.5% a/o 9-30-20 https://tinyurl.com/y652nxpr
13 LARGEST SHAREHOLDERS a/o 9-30-20:
1. Eastern Capital (Kenneth Dart): 4,300,992 7.6% (a/o 8-21-19 14A/Proxy: https://tinyurl.com/y9c972fa – orig. 13G filed 11-2015)
2. Tappan Street (Prasad Phatak): 4,285,000 7.6% (a/o 12-31-19 13G: https://tinyurl.com/wlcwnnv )
3. Blackrock Inc. (Larry Fink): 3,834,816 6.8% (-111,172 a/o 9-30-20 Nasdaq Inst.)
4. IsZo Capital Mgt. (Brian Sheehy): 3,459,888 6.1% (-88,144 a/o 9-30-20 Nasdaq Inst.)
5. Millennium Mgt. 2,678,984 4.7% (+633,918 a/o 9-30-20 Nasdaq Inst.)
6. Vanguard Group 2,659,738 4.7% (-19,553 q/e 9-30-20 Nasdaq Inst.)
7. Snyder Capital 2,302,621 4.1% (-2,258 a/o 9-30-20 Nasdaq Inst.)
8. Altravue Capital 1,973,349 3.5% (+39,534 a/o 9-30-20 Nasdaq Inst.)
9. Wellington Mgt. 1,503,162 2.7% (+236,947 a/o 9-30-20 Nasdaq Inst.)
10. Sargent Invest. Grp. 1,052,099 1.9% (-11,000 a/o 9-30-20 Nasdaq Inst.)
11. State Street 992,280 1.8% (-65,922 a/o 9-30-20 Nasdaq Inst.)
12. Portolan Capital 963,374 1.7% (+528,662 a/o 9-30-20 Nasdaq Inst.)
13. Silvercrest Asset Mgt. 878,805 1.6% (-16,746 a/o 9-30-20 Nasdaq Inst.)
Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
INSIDER-Trans: https://tinyurl.com/ycpw4j9z (formerly PPHM thru 2017: http://tinyurl.com/ypkow8 )
Short Interest, updated twice a month: https://www.nasdaq.com/symbol/cdmo/short-interest
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/yymtzcm9
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3) http://tinyurl.com/yd46m8py
AVID TEAM: https://avidbio.com/leadership/ - Open Jobs: https://avidbio.applicantpro.com/jobs
7-30-20: Nicholas Green (ex-Therapure Biopharma) becomes President/CEO of Avid - 6-25-20 PR: https://tinyurl.com/yczapcc7
4-13-20: Avid Hires 2 Senior Directors of Bus. Dev: Jason C. Brady & Sylvia Hinds https://tinyurl.com/sq2679g
1-8-20: Avid Appoints Timothy Compton as Chief Commercial Officer (repl. Tracy Kinjerski) https://tinyurl.com/ydww58sn
7-26-19: Catherine Mackey, PhD (ex Pfizer VP) joins Avid's BOD, replacing Joel McComb https://tinyurl.com/y3xhqmvm
5-8-19: Richard (Rick) B. Hancock named Interim President/CEO; Roger Lias resigns https://tinyurl.com/y4pqdwyc
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO https://tinyurl.com/ychz45p2
7-16-18: Michael Faughnan (ex-Lonza/WuXi Biologics) joins Avid as Sr.Dir./BusDev/WestC https://tinyurl.com/yaozdggz (Left 5-2019)
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast https://tinyurl.com/ybvrwn2l (left 12-2019)
5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences https://tinyurl.com/y7tpswaw
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway" https://tinyurl.com/ybnjzbv6
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s CEO and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s (left 5-8-19)
11-29-17: Tracy L. Kinjerski joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc (Left 1-8-2020)
Profiles of all 7 BOD members: http://ir.avidbio.com/corporate-governance/board-of-directors
...Joseph Carleone/Chair, Nicholas Green(CEO), Richard Hancock, Gregory Sargen, Mark Bamforth, Patrick Walsh, Catherine Mackey
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/y3jo2rv7
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/y6ydcaof
ANALYST COVERAGE: http://ir.avidbio.com/analyst-coverage
Also see: https://www.marketbeat.com/stocks/NASDAQ/CDMO/price-target
Janney Montgomery Scott - Paul Knight PT=$10
H.C. Wainwright & Co. - Joseph Pantginis PT=$9
Craig-Hallum Capital Group - Matt G. Hewitt PT=$10
First Analysis Securities - Joseph Munda PT=$7.50
Stephens Inc. - Jacob Johnson PT=11 (10=>11 9-2-20)
FINANCIALS & BUSINESS DEV.:
2-3-21: Avid to Mfg. CV19 Therapeutic Lenzilumab for Humanigen https://tinyurl.com/1hzzksxa
8-26-20: Mapp Biopharmaceutical signs w/Avid for ClinDev of Antiviral Antibody (MBP091) https://tinyurl.com/yxwvr949 BARDA #HHSO100201900018C($16.5M+Opt/$30M), see: https://tinyurl.com/yye8t5nx
8-20-20: Oragenics signs Dev/Mfg Agreement with Avid for COVID-19 Vaccine “TerraCoV2” https://tinyurl.com/yxqg3w4v
8-6-20: Iovance Biotherapeutics signs w/Avid(+Aragen) to Dev+Mfg. IOV-3001 (IL-2 Analog) https://tinyurl.com/y2lgzh6x
7-28-20: Avid Teams with Argonaut to add “Parenteral Fill-Finish Services” https://tinyurl.com/y2lgzh6x
5-6-20: Avid Teams with Aragen to speed up drug dev./delivery timelines https://tinyurl.com/ycuu2m5r
4-23-20: Avid receives $4.4M PPP/CV19 Loan (can apply for forgiveness) 8K: https://tinyurl.com/yaltupxa
...5-12-20: Avid Pays Back $4.4M PPP/CV19 Loan (“New SBA Guidance/abundance of caution”) 8K: https://tinyurl.com/y993tkk6
3-10-20: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY20/Q3 (q/e 1-31-20): https://tinyurl.com/s9cmzmf
......Avid FY20 (fye 4-30-20) revenues guidance: $55-59M; committed backlog=$58mm at 1-31-2020.
7-8-19: Avid Signs New Top10 Global Pharma and Expands Existing Cust. Relationship https://tinyurl.com/yyq8zgb9
6-27-19: "The 5 new clients signed in late FY2018 contributed significantly to revenue diversification in FY2019." SEE CUST SPLITS for FY19: http://tinyurl.com/y5j4dlsv
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)” https://tinyurl.com/y89whc8d
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s) https://tinyurl.com/y8jvwleq http://www.acumenpharm.com
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease) https://tinyurl.com/yd5xhcx8 http://www.enzyvant.com
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) https://tinyurl.com/y9z54f4x “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta
FACILITIES: https://avidbio.com/facilities/
10-8-19: Avid Announces Completion of Expansion of Process Dev. Capabilities & Labs https://tinyurl.com/y3hfwst9
...will “significantly accelerate Avid’s ability to drive efficient & rapid on-boarding of new cust. pgms progressing to mfg.”
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18) https://tinyurl.com/y89whc8d
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/y5jmfpo3
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/y539yut4
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) http://tinyurl.com/y2sqoy2u & http://tinyurl.com/kmdgq8t
PRESENTATIONS & ARTICLES: https://avidbio.com/events/
Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.: https://tinyurl.com/y4cbjjrc
5-18-20: Avid Listed In Top CMO Awards Article https://tinyurl.com/yb5cnh6m
...”Avid received 5 CMO Leadership Awards categories, incl. 2 Champion designations: Expertise & Service.”
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity” https://tinyurl.com/ybtuk29m
Sept2018/BioTechWEEK: Tracy Kinjerski (VP/BusOP) interview: Avid’s differentiators (6mins.) https://www.youtube.com/watch?v=x3tzo4pZivk
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow https://tinyurl.com/yanwk9yo
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz
CONFERENCE CALLS & ASM's:
12-2-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript https://tinyurl.com/y66xk888
10-20-20 Annual Shareholders Meeting - Replay (9:45): https://www.virtualshareholdermeeting.com/CDMO2020 (Control# not needed)
9-1-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript https://tinyurl.com/y329llow
...CEO N.Green: ”My first few weeks have done nothing but confirm my view that I believe Avid to be a strong and state-of-the-art company with significant opportunity for growth."
6-30-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript https://tinyurl.com/y9zbgmos
...RickH: "Based on our customers' growing demand and our expanding business development activity, we believe that we will significantly increase capacity utilization in 2021 and beyond. Accordingly, we have entered into a new phase of planning for the expansion that will support our growing business in the years to come.”
...”Top10 Pharma customer added 7-2019 named in 10-K: GILEAD SCIENCES.”
3-10-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript https://tinyurl.com/s9cmzmf
12-9-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/tfewuzc
9-5-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6t8zfur
6-27-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6zdjyu2
...Rick Hancock, "Most importantly, during Q4, the Company achieved positive income, generating cash from dev. & mfg. operations for the 1st time since the beginning of the CDMO transition (Jan'18)."
3-11-19: Qtly. Conf. Call (Lias/Hart) PR & Transcript http://tinyurl.com/yy6dvjvc
12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript https://tinyurl.com/y9n374kp
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report https://tinyurl.com/yctfzhlb
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript https://tinyurl.com/y8oc6hx8
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript https://tinyurl.com/yaozdggz
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript https://tinyurl.com/yakdl4wj
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports https://tinyurl.com/yca6enbr 12-7-17 PROXY/14A: https://tinyurl.com/y7qprpg9
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay
Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.
**FULL PPHM=>CDMO Transition History (Ronin/SWIM): https://tinyurl.com/ybqvzwhg
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP) https://tinyurl.com/y8vhjow4
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...12-13-18/8-K: Overview of Oncologie sale: https://tinyurl.com/yab9c6cr
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see: https://tinyurl.com/yakdl4wj
Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
https://tinyurl.com/y8pq4rhc
Of Interest (post Oncologie Sale):
Oncologie's website: https://oncologie.com/true-home-v2/ NEWS: https://oncologie.com/newsroom/
4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters https://tinyurl.com/ycgjhvqa
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK https://tinyurl.com/y7fd9vdb
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund https://tinyurl.com/ybrrbgg7
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.” https://tinyurl.com/ycb8r7sm
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84 https://tinyurl.com/y9n374kp
11-4-19/PharmaBoardroom: Interview with Oncologie CEO Laura Benjamin discussing the 2 ongoing Bavi Trials w/Keytruda (USA UK Taiwan S.Korea) https://tinyurl.com/ydf6zhsv
...Dr. Benjamin, "We have high expectations of bavituximab and have obtained the global rights for this compound."
...Ongoing Trial #1 (N=80): Open Label, Bavi+Keytruda Adv. Gastric/GEJ Cancer https://clinicaltrials.gov/ct2/show/NCT04099641
......1-17-2020 ASCO/GI Poster: https://oncologie.com/wp-content/uploads/2020/01/2020-01-17-ASGO-GI-poster-final-draft.pdf
...Ongoing Trial #2 (N=34 UTSW): Open Label, Bavi+Keytruda Adv. Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT03519997
6-11-20/Fiercebiotech: Oncologie Reels In $80M To Push Clinical Pgms/Build Pipeline https://tinyurl.com/yany8f34 & https://tinyurl.com/y8p9artk
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |